Shanghai Runda Medical Technology posts semi-annual loss as revenue declines

Shanghai Runda Medical Technology, a major player in the IVD circulation and services industry, released its 2025 semi-annual report showing a net loss of -120,652,208.04 yuan, a decrease of 232.14% compared to the same period last year. Total operating revenue for the first half of 2025 was 3,470,487,876.09 yuan, down 16.08% year-on-year, primarily due to price reductions from centralized procurement and other medical policies. Despite implementing cost-reduction measures, fixed expenses such as depreciation and staff salaries remained high, contributing to the net loss.

The company's total assets decreased by 3.61% to 13,788,587,401.19 yuan, with net assets attributable to shareholders falling by 3.18% to 4,216,107,828.51 yuan. However, cash flow from operating activities increased by 76.99% to 153,796,642.30 yuan.

In related news, Shanghai Runda Medical Technology also announced the proposal to cancel its supervisory board and amend its articles of association, with supervisory board functions to be transferred to the audit committee of the board of directors. Additionally, the company is seeking to reappoint BDO China Shu Lun Pan Certified Public Accountants LLP as its auditor for 2025. A shareholder meeting is scheduled for September 12, 2025, to address these proposals.